Pazopanib – Targeted Therapy

Pazopanib is a second-generation oral multi-kinase inhibitor designed for the targeted therapy of solid tumors. The drug effectively blocks several types of tyrosine kinase receptors that play a key role in tumor growth and the formation of its vascular network.

The mechanism of action of pazopanib involves inhibiting vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α, -β), and the stem cell factor receptor (c-KIT). Blocking these pathways results in a potent anti-angiogenic effect—the tumor is deprived of the ability to create new vessels for its nutrition, which slows its growth and prevents metastasis. Furthermore, direct action on tumor cell receptors inhibits their division and survival.

The drug is available in tablet form for daily administration. It significantly increases progression-free survival in patients with advanced renal cell carcinoma and soft tissue sarcomas.

Wikipedia page

Indications

Pazopanib is used in oncology for the therapy of the following pathologies:

Advanced Renal Cell Carcinoma (RCC): as first-line therapy or in patients who have previously received cytokine therapy.
Soft Tissue Sarcoma (STS): treatment of specific subtypes of advanced sarcomas in patients who have previously received chemotherapy.
Progressive Forms: the drug is indicated for metastatic processes when surgical intervention is not possible.

Dosage and administration

The pazopanib dosing regimen requires strict adherence to the rules of administration.

Standard Dose: 800 mg (two 400 mg tablets) once daily.
Administration Rules: tablets should be taken on an empty stomach—at least 1 hour before or 2 hours after a meal. They must not be crushed or chewed.
Missed Dose: if there are less than 12 hours remaining until the next dose, the missed dose should not be taken.
Food Interactions: grapefruit juice and fatty foods can significantly increase the concentration of the drug, increasing the risk of toxicity.
Dose Adjustment: if side effects occur or liver function is impaired, the physician may reduce the dosage in 200 mg increments.

The use of pazopanib is restricted or prohibited in the following cases:

Hypersensitivity: allergic reactions to pazopanib or any components of the tablet.
Severe Hepatic Impairment: the drug is metabolized in the liver; therefore, serious functional impairment is a contraindication.
Severe Renal Impairment: due to limited clinical experience in this population.
Pregnancy and Lactation: the drug is embryotoxic; breastfeeding is prohibited during therapy.
Pediatric Use: safety in patients under 18 years of age has not been established.

Pazopanib therapy requires regular monitoring of blood pressure and liver function:

Liver Enzymes: elevation of ALT, AST, and bilirubin levels (hepatotoxicity).
Cardiovascular System: arterial hypertension (increased blood pressure) — occurs very frequently.
Gastrointestinal: diarrhea, nausea, vomiting, and changes in taste (dysgeusia).
Dermatologic: hair color changes (depigmentation), skin rash, and hand-foot syndrome.
General Symptoms: fatigue, decreased appetite, and weight loss.

Frequently Asked Questions

Pazopanib is a targeted therapy belonging to the group of tyrosine kinase inhibitors. It works by blocking the growth of new blood vessels that supply the tumor (angiogenesis). Its primary indications are advanced renal cell carcinoma (RCC) and certain types of soft tissue sarcoma.

Votrient is the original drug by Novartis (formerly GSK). Indian generics (e.g., by Natco or Hetero) available on Unifarm contain the same active ingredient and offer the same clinical efficacy but at a significantly lower cost, which is crucial for long-term treatment.

The standard dose is 800 mg (usually four 200 mg tablets) once daily. It is critical to take the medication strictly on an empty stomach—at least 1 hour before or 2 hours after a meal. Tablets should be swallowed whole; do not crush or chew them.

No, you should avoid grapefruit and grapefruit juice while taking pazopanib. They contain substances that block the drug's breakdown in the body, which can lead to dangerously high levels in the bloodstream and increased side effects.

Common side effects include diarrhea, hair color changes (whitening/depigmentation), hypertension, nausea, and fatigue. The drug can also affect liver function, so regular liver function tests are required during the first months of treatment.

We offer pazopanib generics at prices significantly more affordable than European counterparts. The price depends on the manufacturer and the current exchange rate. You can always check the latest pricing in our website catalog or contact a manager for details.

To order, add the product to your cart on the Unifarm website or give us a call. Delivery is available throughout Ukraine via postal services. We guarantee the authenticity of the medications and compliance with transportation requirements.